Clinical Trial

Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma

Name: Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma — clinical trial record (NCT07269639)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Go-Pro-DLBCL

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This trial is a proof-of-concept, pilot study, phase I/II clinical trial aimed at generating preliminary data on the combination of golcadomide, poseltinib, and rituximab.

Trial Details

NCT Number	NCT07269639
Lead Sponsor	Seoul National University Hospital
Conditions	Large B-Cell Lymphoma (LBCL)
Enrollment	20 participants
Start Date	2026-01-01
Primary Completion	2027-12-01 (estimated)
Study Completion	2028-09-01 (estimated)
Updated on ClinicalTrials.gov	2025-12-08